等待开盘 11-18 09:30:00 美东时间
-0.150
-1.54%
11月17日,Bicara Therapeutics(BCAX)收跌2.69%,报9.75美元,成交额1074.52万美元,市值6.47亿美元。 行情数据 •...
11-17 06:55
今日重点评级关注:韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从42美元升至44美元;HC Wainwright & Co.:维持WhiteFiber"买入"评级,目标价从34美元升至36美元
11-12 19:19
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Bicara Therapeutics shares are trading higher after the company announced Q3 financial results. The company reported substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC
11-10 00:31
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.81) by 28.4 percent. This is a 55.22 percent decrease over losses of $(0.67) per share from the same period last year.
11-09 20:33
11月7日,Bicara Therapeutics(BCAX)收涨5.62%,报8.65美元,成交额873.19万美元,市值5.72亿美元。 行情数据 • 开盘...
11-07 06:58
Bicara Therapeutics granted a stock option to a new employee under its 2026 Inducement Plan, awarding 50,000 shares with an exercise price of $7.93, vesting over four years. The company, focused on bifunctional therapies for solid tumors, highlights its lead program, ficerafusp alfa, targeting EGFR and TGF-β to enhance anti-tumor activity and survival.
11-04 13:30
U.S. stocks were mixed, with the Dow Jones falling around 200 points on Tuesday. Shares of Fabrinet (NYSE:FN) rose sharply after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Also, the company authorized a repurchase of ...
11-04 01:02
10月31日,Bicara Therapeutics(BCAX)收跌6.17%,报9.13美元,成交额3719.92万美元,市值6.04亿美元。 行情数据 •...
10-31 05:59
今日重点评级关注:Canaccord Genuity:维持Wave Life Sciences"买入"评级,目标价从42美元升至44美元;Canaccord Genuity:维持Pharming Group"买入"评级,目标价从38美元升至41美元
10-30 12:30